Epidemiological Screening of IL10RA Mutation Rate in China (Yes)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03097731
Recruitment Status :
(Preliminary tests found that some newborns heel blood amount could not meet the test needs.)
The presentation of IBD in early childhood is uncommon and the monogenetic defects, especially IL-10 signaling pathway play a key role in very early onset inflammatory bowel disease (VEO-IBD). IL-10 or IL-10R deficiency associated VEO-IBD is considered a rare disorder. To date, there were about 60 cases were reported all over the word. But in our Chinese VEO-IBD Collaboration Group, 42 patients with biallelic mutations affecting IL10R genes were identified from 93 VEO-IBD patients, and the mutation sites are highly concentrated, including 83.9% (26/31) with p.R101W and 55% p.T179T (17/31) mutation, and the proportion of patients from Henan( A province of China) is higher. So we speculate that IL-10RA mutation may not be very rare, and the frequency of heterozygote subjects might be higher than suspected.
Condition or disease
Digestive System Disease
The mutation rates of p.R101W and p.T179T IL10RA in Henan newborn.
Is there any clinical symptoms in children with IL-10RA-deficient? and the onset of the symptoms.
Whether the intestinal permeability is normal in heterozygote subjects.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
up to 28 Days (Child)
Sexes Eligible for Study:
In the study period, all newborns in the selected hospital were included.
In the study period, all newborns in the selected hospita
Children whose guardian refused to participate in the study